KR20180062763A - Composition for anti-inflammatory - Google Patents
Composition for anti-inflammatory Download PDFInfo
- Publication number
- KR20180062763A KR20180062763A KR1020160162821A KR20160162821A KR20180062763A KR 20180062763 A KR20180062763 A KR 20180062763A KR 1020160162821 A KR1020160162821 A KR 1020160162821A KR 20160162821 A KR20160162821 A KR 20160162821A KR 20180062763 A KR20180062763 A KR 20180062763A
- Authority
- KR
- South Korea
- Prior art keywords
- inflammatory
- dermatitis
- present
- composition
- hyaluronic acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 57
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 31
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 31
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 31
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 27
- -1 glyceryl glucoside Chemical class 0.000 claims abstract description 25
- 229930182478 glucoside Natural products 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 102000004889 Interleukin-6 Human genes 0.000 claims description 21
- 108090001005 Interleukin-6 Proteins 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 21
- 229940100601 interleukin-6 Drugs 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 19
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 19
- 102000004890 Interleukin-8 Human genes 0.000 claims description 17
- 108090001007 Interleukin-8 Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 16
- 229940096397 interleukin-8 Drugs 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 229930003935 flavonoid Natural products 0.000 claims description 13
- 235000017173 flavonoids Nutrition 0.000 claims description 13
- 150000002215 flavonoids Chemical class 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000005487 catechin Nutrition 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229960001285 quercetin Drugs 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 206010024229 Leprosy Diseases 0.000 claims description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 3
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 3
- 229940117893 apigenin Drugs 0.000 claims description 3
- 235000008714 apigenin Nutrition 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 235000007240 daidzein Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010053177 Epidermolysis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 235000006539 genistein Nutrition 0.000 claims 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 1
- 229940045109 genistein Drugs 0.000 claims 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 1
- 208000012410 herpes zoster dermatitis Diseases 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- 206010061218 Inflammation Diseases 0.000 description 28
- 230000004054 inflammatory process Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 238000009472 formulation Methods 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 8
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 5
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 1
- 229930013799 (-)-catechin Natural products 0.000 description 1
- 235000007331 (-)-catechin Nutrition 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y10S514/857—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 독성이 없고, 염증성 피부질환 관련 매개 인자의 발현을 효과적으로 억제하여 상승된 항염 활성을 갖는 항염 조성물에 관한 것이다.The present invention relates to an anti-inflammatory composition which is free of toxicity and effectively inhibits the expression of an inflammatory skin disease-related mediator and has an elevated anti-inflammatory activity.
피부의 염증반응은 외부의 생물학적인 원인(세균, 바이러스, 기생충), 물리학적인 원인(기계적인 자극, 열, 방사선, 전기), 화학적인 원인 등으로 인한 세포나 조직이 손상을 입거나 파괴되었을 때, 그 손상을 최소화하고 손상된 부위를 원상으로 회복시키기 위하여 국소적으로 일어나는 면역반응을 의미한다.Skin inflammation is caused by damage or destruction of cells or tissues due to external biologic causes (bacteria, viruses, parasites), physical causes (mechanical stimulation, heat, radiation, electricity) , A localized immune response that minimizes the damage and restores the damaged site to its original state.
상기 염증반응은 생체를 보호하고, 조직 손상으로 생성된 산물들을 제거하는데 유용한 방어 메카니즘으로, 국소 혈관과 체액에 존재하는 각종 염증 매개인자 및 면역세포가 관련되어 효소 활성화, 염증매개물질 분비, 체액침윤, 세포 이동, 조직 파괴, 홍반, 부종, 발열 또는 통증 등을 수반하거나 상기와 같은 증상에 의해 기능장애를 유발하기도 한다. The inflammatory reaction is a useful defense mechanism to protect the living body and to remove the products produced by the tissue damage. Various inflammatory mediators and immune cells that are present in the local blood vessels and body fluids are related to the enzyme activation, inflammatory mediator secretion, , Cell migration, tissue destruction, erythema, edema, fever or pain, or may cause dysfunction due to such symptoms.
이러한 염증반응은 다양한 생화학적인 현상이 관여하고 있으며, 특히 면역세포에 의해 생산되는 염증반응과 관련된 다양한 효소에 의해 반응이 개시되거나 조절되기도 한다. 구체적으로, 상기 면역세포들은 히스타민(histamine), 일산화질소(nitric oxide, NO) 또는 프로스타글라딘 E2(prostaglandin E2, PGE2) 등의 도움으로 혈관을 통해 손상된 부위로 이동하여 염증반응을 개시한다. 상기 손상된 부위로 이동한 면역세포는 TNF-α(tumor necrosis factor-α), IL-1β(interleukin-1β) 또는 IL-6(interleukin-6)와 같은 사이토카인(cytokine)이나 MIP-1, IL-8 또는 MCP-1등과 같은 케모카인(chemokine)을 분비하여 직접적인 외부침입물질을 파괴하거나 다른 면역세포들을 모아 염증반응을 개시한다.These inflammatory reactions are involved in various biochemical phenomena, and in particular, the reactions are initiated or controlled by various enzymes involved in the inflammatory response produced by immune cells. Specifically, the immune cells migrate to the injured region via blood vessels with the help of histamine, nitric oxide (NO) or prostaglandin E2 (PGE2), and initiate an inflammatory reaction. The immune cells migrated to the injured site are cytokines such as TNF-alpha, IL-1 beta (interleukin-1 beta) or IL-6 (interleukin-6) -8 or MCP-1 to kill direct external invasive substances or collect other immune cells to initiate an inflammatory response.
상기 염증반응을 일으키는 interferon-γ, lipoteichoic acid, lipopolysaccharide(LPS) 등의 염증유발 물질이나 다양한 염증 유도 사이토카인에 노출될 경우, iNOS(inducible Nitric Oxide synthase)와 COX-2(cyclooxygenase-2)가 발현되어, NO와 PGE2가 과량 생성된다. 이들 여러 염증 개시인자들(iNOS, COX-2, TNF-α, IL-6 등)은 활성화된 NF-κB에 의해 전사가 촉진되며, 이로 인해 NO가 필요이상으로 생성되면 쇼크에 의한 혈관확장, 염증반응에 의해 유발되는 조직손상, 돌연변이유발(mutagenesis), 신경조직의 손상을 일으키거나 만성 염증을 유발하여 더욱 더 심각한 조직의 손상을 가져올 수 있다.Expression of iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) when exposed to inflammation-inducing substances such as interferon-γ, lipoteichoic acid and lipopolysaccharide (LPS) And NO and PGE2 are excessively produced. These inflammatory initiators (iNOS, COX-2, TNF-α, IL-6, etc.) promote transcription by activated NF-κB, and if NO is produced unnecessarily, Tissue damage caused by inflammatory reactions, mutagenesis, damage to nerve tissue, or even chronic inflammation leading to more severe tissue damage.
현재 염증성 피부질환의 예방 및 치료를 위해, 이부프로펜과 같은 합성의약제제, 항히스타민제, 스테로이드, 코티손, 면역억제제, 면역 항진제 등이 사용되고 있으나 치료효과가 일시적이거나 단순 증상완화, 과민반응, 면역체계 악화 등의 부작용이 많고, 염증의 근본적인 치료에는 한계를 가졌다. 또한, 특허문헌 1 내지 4 에는 천연 추출물을 이용한 항염 기능을 가지는 화장료 조성물을 개발하기 위한 다양한 시도가 개시되어 있으나 이에 의한 또 다른 피부자극 또는 변색 등의 이유로 그 사용량이 제한되거나 물에 대한 용해도가 좋지 않아 실제 제품 적용시 용도의 제한으로 인하여 실질적인 효과를 거두기 어려웠다. Currently, synthetic medicines such as ibuprofen, antihistamines, steroids, cortisone, immunosuppressants, and immunosuppressive agents are used for the prevention and treatment of inflammatory skin diseases, but the therapeutic effect is temporary, simple symptom relief, hypersensitivity reaction, And there was a limit to the fundamental treatment of inflammation. In addition, Patent Literatures 1 to 4 disclose various attempts to develop a cosmetic composition having a anti-inflammatory function using a natural extract. However, due to other reasons such as skin irritation or discoloration, the use amount thereof is limited or the solubility in water is poor It was difficult to achieve practical effects due to limitations in application of actual products.
이에, 본 출원인은 염증성 피부질환 관련 매개 인자인 염증 유도 사이토카인이나 케모카인의 활성 억제 정도에 대한 연구를 심화한 결과, 보습성분으로 알려진 특정 성분의 조합에서 사이토카인(IL-6 등) 및 케모카인(IL-8, MCP-1 등)의 발현 억제에 효과를 보일 뿐 아니라 단독 성분으로 사용되는 경우와 비교시 현저한 상승 효과를 보임을 발견하여, 이를 포함하는 항염 조성물을 제공하고자 본 발명을 완성하였다.As a result of intensifying studies on the degree of inhibition of the inflammatory cytokine or chemokine, which is an inflammatory skin disease-related mediator, the present applicant has found that a combination of specific components known as moisturizing agents can inhibit cytokine (IL-6 etc.) and chemokine IL-8, MCP-1, etc.) as well as a remarkably synergistic effect in comparison with the case of using it as a sole component, and completed the present invention to provide a anti-inflammatory composition comprising the same.
본 발명의 목적은 피부 부작용을 유발하지 않으며, 피부 염증을 효과적으로 억제할 수 있는 항염 조성물을 제공하는 것이다.It is an object of the present invention to provide a anti-inflammatory composition that does not cause skin side effects and can effectively inhibit skin inflammation.
본 발명의 또 다른 목적은 우수한 피부 밀착성으로 향상된 보습효과의 제공과 함께 쿨링 효과를 제공하여 피부 진정 효과를 극대화할 수 있는 항염 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-inflammatory composition which can provide an improved moisturizing effect with excellent skin adhesion and provide a cooling effect, thereby maximizing a skin soothing effect.
본 발명은 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함하는 항염 조성물을 제공한다.The present invention provides a anti-inflammatory composition comprising glyceryl glucoside and hyaluronic acid as an active ingredient.
본 발명의 일 양태에 따른 항염 조성물은 사이토카인 및 케모카인을 조절하거나 염증 매개분자의 발현 억제에 의해 자극과 염증을 조절할 수 있다. 상세하게, 본 발명에 따른 항염 조성물은 인터루킨-6(interleukin-6, IL-6) 등과 같은 사이토카인이나 인터루킨-8(interleukin-8, IL-8), 단핵구 화학유인 단백질-1(monocyte chemotactic protein-1, MCP-1) 등과 같은 케모카인에 의해 과도하게 생성된 일산화질소(nitric oxide, NO)와 프로스타글란딘(prostaglandin E2, PGE2) 등을 효과적으로 억제함으로써, 염증반응을 억제 및 차단할 수 있다. The anti-inflammatory composition according to an embodiment of the present invention can regulate stimulation and inflammation by regulating cytokines and chemokines or inhibiting the expression of inflammatory mediators. In detail, the anti-inflammatory composition according to the present invention is useful as a cytokine such as interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemotactic protein (Prostaglandin E 2 , PGE 2), which are excessively produced by chemokines such as MCP-1 and MCP-1, and the like, thereby suppressing and blocking the inflammatory reaction.
본 발명의 일 양태에 따르면, 염증 개선용 화장료 조성물을 제공한다.According to one aspect of the present invention, there is provided a cosmetic composition for improving inflammation.
또한 본 발명의 일 양태에 따르면, 염증성 피부 질환의 예방 및 개선용 약학 조성물을 제공한다.According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing and ameliorating an inflammatory skin disease.
본 발명에 따르면, 사이토카인의 조절은 물론 염증 매개분자인 일산화질소, 프로스타글란딘(prostaglandin E2, PGE2)의 활성을 억제함으로써, 염증 반응을 억제 및 차단할 수 있다. 특히 본 발명에 따르면, 대식세포에서 염증 관련 사이토카인(IL-6 등)과 케모카인(IL-8, MCP-1 등)을 효과적으로 억제시킴과 동시에 LPS 자극 후 대식세포에서 분비되는 NO형성을 억제함으로써, 탁월한 항염 효과를 갖는다. According to the present invention, it is possible to inhibit and block the inflammatory reaction by inhibiting the activity of inflammation mediator molecules, such as nitrogen monoxide, prostaglandin (prostaglandin E 2 , PGE 2), as well as the regulation of cytokines. In particular, the present invention effectively inhibits inflammation-related cytokines (such as IL-6) and chemokines (such as IL-8 and MCP-1) in macrophages and inhibits the formation of NO secreted by macrophages after LPS stimulation , And has an excellent anti-inflammatory effect.
더욱이, 본 발명에 따른 항염 조성물은 독성 또는 부작용을 초래하지 않아 다양한 제형의 화장료 및 약학 조성물로 안전하게 적용할 수 있다.Furthermore, the anti-inflammatory composition according to the present invention does not cause toxicity or side effects, and thus can be safely applied to various cosmetic formulations and pharmaceutical compositions.
본 발명에 따른 항염 조성물에 대하여 이하 상술하나, 이때 사용되는 기술 용어 및 과학 용어에 있어서 다른 정의가 없다면, 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 가지며, 하기의 설명에서 본 발명의 요지를 불필요하게 흐릴 수 있는 공지 기능 및 구성에 대한 설명은 생략한다.The anti-inflammatory composition according to the present invention will be described in detail below. Unless otherwise defined, technical terms and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. The description of known functions and configurations that may unnecessarily obscure the gist of the present invention will be omitted.
본 발명에서 사용되는 용어, "염증"은 세포나 조직이 어떠한 원인에 의해 손상을 받으면 그 반응을 최소화하고 손상된 부위를 원상으로 회복시키려는 일련의 방어 목적으로 나타나는 현상을 의미하는 것으로, 신경, 혈관, 임파관, 체액 반응, 세포 반응을 일으켜 결과적으로 통증, 부종, 발적, 발열 등을 일으켜 기능장애를 유발하는 것을 통칭한다. 상기 염증으로 인한 염증성 피부질환은 아토피성 피부염, 건선, 접촉성 피부염, 습진성 피부염, 광선 피부염, 지루 피부염, 포진성 피부염, 편평태선, 경화태선, 괴저성 농피증, 천포창, 수포성 표피박리증, 전신성 경화증, 피부근염, 다발성 근염, 염증성 근병변, 나병, 세자리 증후군 등으로 이루어진 군 중에서 선택된 1종 이상일 수 있고, 두드러기(urticaria), 곤충 알러지, 식품 알러지 및 약품 알러지 등의 알러지성 피부염 또한 동일 범주에 속한다.As used herein, the term "inflammation " refers to a phenomenon that occurs when a cell or tissue is damaged due to any cause, for the purpose of minimizing the reaction and restoring the damaged part to the original state, Which causes pain, swelling, redness, fever, and the like, resulting in dysfunction, dysfunction, and dysfunction. The inflammatory skin diseases caused by inflammation are selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, photodermatitis, seborrheic dermatitis, herpes dermatitis, herpes dermatitis, squamous cell, And may be at least one selected from the group consisting of inflammation, scleroderma, dermatomyositis, multiple myositis, inflammatory muscle lesions, leprosy, and three-point syndromes, and allergic dermatitis such as urticaria, insect allergies, food allergies and drug allergies Belongs.
또한, 상기 염증은 생체 내에서 다양한 생화학적 현상에 의해 발생되며, 특히, 아라키돈산(arachidonic acid)으로부터 프로스타글란딘(prostaglandin)을 생합성하는데 관련된 효소인 시클로옥시게나제(Cyclooxygenase, COX)와 L-아르기닌(L-arginin)으로부터 일산화질소(nitric oxide, NO)를 생성시키는 효소인 니트릭옥사이드 신타제(nitric oxide synthase, NOS)는 염증 반응을 매개하는데 있어서 중요한 역할을 하고 있는 것으로 알려져 있다.In addition, the inflammation is caused by various biochemical phenomena in vivo. In particular, the inflammation is caused by an enzyme involved in biosynthesis of prostaglandin from arachidonic acid, such as cyclooxygenase (COX) and L-arginine Nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO) from L-arginine, is known to play an important role in mediating inflammatory responses.
본 발명에서 사용되는 용어, "프로스타글란딘“은 몸속에서 합성되는 일종의 생리활성 호르몬으로서, 염증반응을 조절하는 기능이 있다. 상기 프로스타글란딘은 PGE1, PGE2, PGE3로 3종류가 있으며, PGE1과 PGE3는 염증을 억제하고, PGE2는 염증을 유발시킨다. 상기 프로스타글란딘은 아라키돈산을 전구체로 하여 시클로옥시게나제(Cyclooxygenase, COX)를 통해 생합성 된다.The term " prostaglandin " used in the present invention is a kind of physiologically active hormone synthesized in the body and has a function of regulating the inflammatory reaction. There are three types of prostaglandins, PGE1, PGE2 and PGE3. PGE1 and PGE3, , And PGE2 induces inflammation. The prostaglandin is biosynthesized through cyclooxygenase (COX) using arachidonic acid as a precursor.
본 발명에서 사용되는 용어, "시클로옥시게나제(Cyclooxygenase, COX)"는 프로스타글란딘의 합성의 제1단계를 촉매하는 효소로서, 아라키돈산에 2분자의 산소를 도입하여, PGE2를 합성하며, 프로스타글란딘 엔도페록시드 신타아제라고도 불린다. 한편 시클로옥시게나제(Cyclooxygenase, COX)도 COX-1, COX-2로 2종류의 이소형태가 존재한다. COX-1는 세포 내에 항상 존재하여 세포보호 작용에 필요한 프로스타글란딘을 합성하는 작용을 하는 반면 COX-2는 염증 반응 시 세포내에서 급격히 증가하여 염증 반응에 중요한 역할을 수행하는 것으로 알려져 있다.The term "cyclooxygenase (COX)" used in the present invention is an enzyme that catalyzes the first step of the synthesis of prostaglandin, wherein two molecules of oxygen are introduced into arachidonic acid to synthesize PGE2, Also called peroxides synthase. On the other hand, cyclooxygenase (COX) also has two types of isoforms, COX-1 and COX-2. It is known that COX-1 is always present in cells to synthesize prostaglandins necessary for cytoprotective action, while COX-2 is known to play an important role in inflammatory reaction by rapidly increasing in cells during inflammatory reaction.
또한, 본 발명에서의 용어, "일산화질소(nitric oxide, NO)"는 각종 사이토카인이나 외부 자극에 의해 유도되는 iNOS(induced NOS)에 의해 발생되며, 세포독성이나 각종 염증 반응을 일으키는 것으로 알려져 있다. 또한, 만성 염증은 iNOS 활성 증가와 관련이 있다고 알려져 있다(Appleton L.et al Adv. Phamacol., 35. 27-28.1996).The term "nitric oxide (NO)" in the present invention is known to be caused by various cytokines or iNOS (induced NOS) induced by external stimuli and causes cytotoxicity or various inflammatory responses . Chronic inflammation is also known to be associated with increased iNOS activity (Appleton L. et al. Pharmacol., 35. 27-28.1996).
본 발명에서 사용되는 용어, "유효성분으로 포함하는"의 의미는 항염 조성물로써, 항염 효과를 나타낼 수 있는 정도의 유효량을 포함하는 것을 의미하는 것일 수 있다.The term "comprising as an active ingredient" used in the present invention means an anti-inflammatory composition, which means that it contains an effective amount to such an extent that it can exhibit anti-inflammatory effect.
본 발명에서 사용되는 용어, "도포"는 임의의 적절한 방법으로 개체의 피부에 본 발명에 따른 조성물을 접촉시키는 것을 의미하며, 이를 통해 해당 조성물을 피부 내부로 흡수시키는 것을 목적으로 한다. The term "application, " as used herein, refers to contacting a composition according to the present invention to the skin of an individual by any suitable method, thereby aiming to absorb the composition into the skin.
본 발명에서 사용되는 용어, "개선"은 본 발명에 따른 조성물의 도포로 염증 상태가 호전되거나 이롭게 변경되는 모든 행위를 말한다.As used herein, the term "improvement" refers to any action that improves or alters the inflammatory state by application of the composition according to the present invention.
발명에서 “용해”는 물을 포함하는 용매에 완전히 녹는 상태뿐만 아니라 미셀 등에 의한 가용화 상태, 또는 수성 용매 중에 균일하게 분산되어 육안으로 투명한 액의 상태를 포함하며, 각 물질의 용해도 측정에 일반적으로 사용되는 시험 방법으로 측정되는 상태를 의미한다. In the invention, " dissolution " includes not only a state of being completely dissolved in a solvent containing water but also a state of being solubilized by micelles or the like, or a state of being visually transparent and uniformly dispersed in an aqueous solvent, Which is measured by the test method.
본 출원인은 염증성 피부질환 관련 매개 인자인 염증 유도 사이토카인의 활성 억제 정도에 대한 연구를 심화한 결과, 보습 성분으로 알려진 특정 성분의 조합에서 항염 효과를 보임을 확인하였다. 또한 본 발명에 따르면, 각 성분의 단순 배합에 따른 예상치 못한 우수한 상승작용적 항염 효과를 나타내었으며, 피부에 대한 자극이 없어, 다양한 양태의 제형으로 안전하게 활용 될 수 있는 새로운 양태의 항염 조성물을 제공할 수 있다.The Applicant has deeply studied the degree of inhibition of the activity of inflammatory cytokine, an inflammatory skin disease-related mediator, and found that the combination of specific ingredients known as moisturizing agents shows anti-inflammatory effects. Further, according to the present invention, there is provided a novel anti-inflammatory composition which exhibits an unexpected superior synergistic anti-inflammatory effect according to the simple combination of each ingredient and has no irritation to the skin and can be safely used in various formulations .
본 발명의 일 양태에 따른 항염 조성물은 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함한다.An anti-inflammatory composition according to an embodiment of the present invention includes glyceryl glucoside and hyaluronic acid as an active ingredient.
본 발명의 일 양태에 따른 항염 조성물은 염증과 관련된 각 수준의 단백질의 발현을 억제할 수 있고, 염증을 직접적으로 유도하는 NO의 분비를 효과적으로 억제 및 차단할 수 있다. 특히, 본 발명에 따르면 대식세포에서 염증 관련 사이토카인(IL-6 등)과 케모카인(IL-8, MCP-1 등)을 효과적으로 억제시킴과 동시에 LPS 자극 후 대식세포에서 분비되는 NO형성을 억제함으로써, 탁월한 항염 효과를 나타낸다. The anti-inflammatory composition according to an embodiment of the present invention can inhibit the expression of proteins at various levels related to inflammation and effectively inhibit and block the secretion of NO that directly induces inflammation. In particular, the present invention effectively inhibits inflammation-related cytokines (such as IL-6) and chemokines (such as IL-8 and MCP-1) in macrophages and inhibits NO formation secreted by macrophages after LPS stimulation , Exhibiting excellent anti-inflammatory effect.
본 발명의 일 양태에 따른 항염 조성물은 우수한 피부 밀착성으로 향상된 보습효과의 제공과 함께 쿨링 효과를 제공할 수 있다는 장점을 가진다. 또한, 본 발명에 따르면 무겁고 미끌거리는 히알루론산 고유의 사용감을 가볍고 산뜻하게 전환시켜 줌으로써, 부드러운 사용감으로 피부에 도포되어 우수한 밀착성으로 상술된 항염 효과를 피부에 효과적으로 전달할 수 있다.The anti-inflammatory composition according to one embodiment of the present invention has an advantage that it can provide an improved moisturizing effect and a cooling effect with excellent skin adhesion. Further, according to the present invention, since the heavy and slippery hyaluronic acid inherent feeling of use is lightly and neatly converted, it is applied to the skin with a soft feeling of use, and the excellent anti-inflammatory effect described above can be effectively delivered to the skin.
이때, 상기 히알루론산은 D-glucuronic acid와 N-acetyl-D-glucosamine이 β-1,3결합으로 연결된 구조가 교대로 반복되어 β-1,4결합으로 연결된 쇄상구조를 가진 것으로, 분자량은 수십만에서 수백만에 이르는 고분자 다당으로 매우 높은 점성을 가진다. 이는 닭의 볏으로부터 추출하거나 발효법 등에 의해, 통상의 방법으로 수득 가능하다. 또한, 본 발명의 일 양태에 따른 히알루론산은 히알루론산의 염 형태 역시 포함한다. 상기 히알루론산의 염으로는 히알루론산 나트륨, 히알루론산 칼륨 등을 들 수 있으나 이외 약학적으로 허용 가능한 모든 염 형태 역시 본 발명에 포함된다. 이때, 상기 히알루론산은 당업계에서 사용되는 것이라면, 고분자 히알루론산, 저분자 히알루론산 등에 제한되지 않는다. 상기 고분자 히알루론산은 중량평균분자량이 500,000 내지 3,000,000 Da인 것일 수 있으며, 상기 저분자 히알루론산은 중량평균분자량이 500,000 Da 미만인 것일 수 있으며, 상술된 보습효과 및 쿨링 효과를 극대화하기 위해서는 고분자 히알루론산 단독 또는 저분자 히알루론산과 고분자 히알루론산 혼합물을 사용하는 것이 좋으나 이에 한정되지 않음은 물론이다.At this time, the hyaluronic acid has a chain structure in which D-glucuronic acid and N-acetyl-D-glucosamine are linked by a β-1,3 bond and alternately repeatedly connected by a β-1,4 bond. To millions of polymeric polysaccharides with very high viscosity. This can be obtained by conventional methods, for example, by extraction from the crest of a chicken or by fermentation. The hyaluronic acid according to an embodiment of the present invention also includes a salt form of hyaluronic acid. Examples of the salt of hyaluronic acid include sodium hyaluronate and potassium hyaluronate, but all pharmaceutically acceptable salt forms are also included in the present invention. At this time, the hyaluronic acid is not limited to polymer hyaluronic acid, low molecular weight hyaluronic acid and the like as long as it is used in the art. The polymer hyaluronic acid may have a weight average molecular weight of 500,000 to 3,000,000 Da, and the low molecular weight hyaluronic acid may have a weight average molecular weight of less than 500,000 Da. In order to maximize the moisturizing effect and the cooling effect, It is preferable to use a mixture of low molecular weight hyaluronic acid and high molecular weight hyaluronic acid, but it is not limited thereto.
본 발명의 일 양태에 따른 항염 조성물에서 상기 글리세릴 글루코사이드 및 히알루론산의 사용량은 제한되지는 않으나, 우수한 밀착성으로 피부에 도포되어 피부 진정 효과를 부여함과 동시에 목적하는 항염 효과를 극대화하기 위한 측면에서 좋게는 글리세릴 글루코사이드 100 중량부를 기준으로, 히알루론산을 10 내지 200 중량부 범위로 포함하는 것일 수 있으며, 보다 좋게는 히알루론산을 50 내지 150 중량부 범위로 포함하는 것일 수 있다.The amount of glyceryl glucoside and hyaluronic acid to be used in the anti-inflammatory composition according to an embodiment of the present invention is not limited, but it is preferable that the glyceryl glucoside and hyaluronic acid are applied to the skin with excellent adhesiveness so as to provide skin soothing effect and maximize the desired anti- Preferably, hyaluronic acid may be contained in an amount of 10 to 200 parts by weight based on 100 parts by weight of glyceryl glucoside, and more preferably, it may include hyaluronic acid in a range of 50 to 150 parts by weight.
본 발명의 일 양태에 따른 항염 조성물은 2개 이상의 수산기를 가지는 용매를 더 포함할 수 있다. 이때, 상기 2개 이상의 수산기를 가지는 용매는 통상의 것이라면 제한되지 않으나, 글리세릴 글루코사이드 및 히알루론산과의 뛰어난 상용성으로 제형 안정성을 높이고, 상호간의 수소 결합에 의해 산뜻한 제형감과 함께 보습 효과를 지속적으로 제공할 수 있다는 측면에서 바람직하게 글리세린 단독 또는 글리세린을 포함하는 혼합 용매일 수 있다. 이때, 상기 글리세린을 포함하는 혼합 용매에 추가되는 2개 이상의 수산기를 가지는 용매는 1,3-프로판디올, 1,3-부탄디올, 1,5-펜탄디올, 1,2-헥산디올, 1,8-옥탄디올 및 1,10-데칸디올 등에서 선택되는 하나 이상일 수 있다. 특히, 상기 글리세린과 1,2-헥산디올, 1,8-옥탄디올 및 1,10-데칸디올에서 선택되는 하나 이상이 혼합된 혼합 용매의 경우, 놀랍게도 상기 글리세릴 글루코사이드와의 조합으로 항균 효과에서, 시너지를 보인다. 또한, 본 발명의 일 양태에 따른 항염 조성물은 상기 글리세린을 포함하는 혼합 용매를 포함하는 경우, 난용성 또는 불용성 물질의 가용화능을 현저하게 향상시킬 수 있다는 측면에서 우선된다.The anti-inflammatory composition according to an embodiment of the present invention may further include a solvent having two or more hydroxyl groups. At this time, the solvent having two or more hydroxyl groups is not limited as long as it is a conventional one, but it is preferable that the solvent is highly compatible with glyceryl glucoside and hyaluronic acid to enhance formulation stability, Preferably glycerin alone or mixed daily for containing glycerin. At this time, the solvent having two or more hydroxyl groups added to the mixed solvent containing glycerin is 1,3-propanediol, 1,3-butanediol, 1,5-pentanediol, 1,2-hexanediol, - octanediol, 1,10-decanediol, and the like. In particular, in the case of a mixed solvent in which at least one selected from the above-mentioned glycerin and 1,2-hexanediol, 1,8-octanediol and 1,10-decanediol is mixed, surprisingly, the combination of glyceryl glucoside And synergy. In addition, the anti-inflammatory composition according to an embodiment of the present invention has priority in that it can remarkably improve solubilization ability of insoluble or insoluble materials when the above-mentioned mixed solvent containing glycerin is included.
상기 2개 이상의 수산기를 가지는 용매의 사용량은 제한되지는 않으나, 조성물 전체 중량 대비 0.5 내지 20 중량%로 포함될 수 있으며, 바람직하게는 1 내지 15 중량%, 보다 바람직하게는 1 내지 10 중량%로 포함될 수 있다. 일예로, 상기 2개 이상의 수산기를 가지는 용매가 혼합 용매일 경우, 글리세린 100 중량부를 기준으로, 글리세린 외 추가 용매를 10 중량부 내지 200 중량부 범위에서 혼합하여 사용될 수 있다.The amount of the solvent having two or more hydroxyl groups is not limited, but may be in the range of 0.5 to 20 wt%, preferably 1 to 15 wt%, more preferably 1 to 10 wt% . For example, when the solvent having two or more hydroxyl groups is used for mixing, the solvent may be added in an amount of 10 parts by weight to 200 parts by weight based on 100 parts by weight of glycerin.
또한, 본 발명의 일 양태에 따른 항염 조성물은 물에 대한 난용성 또는 불용성 물질의 가용화를 돕는다. 이때, 상기 난용성 또는 불용성 물질의 바람직한 일예로는 플라보노이드 성분을 들 수 있다. 상기 플라보노이드는 대부분 배당체 형태의 구조를 가지며, 항산화, 항알러지, 항염, 항균 등의 다양한 생리 활성을 나타내는 것으로 알려져 있다. 허나, 이들은 물에 대한 난용성 또는 불용성의 대표적인 원료로, 이들을 제형으로 적용하기 위해서는 과량의 계면활성제를 사용하여 가용화 처리 후 사용되거나 포집 등의 기술을 이용하여 가용화 처리 후 사용되어야 했다.In addition, the anti-inflammatory composition according to one aspect of the present invention assists in solubilizing water-insoluble or insoluble substances. At this time, a preferable example of the insoluble or insoluble substance is a flavonoid component. Most of the flavonoids have a glycoside-type structure and are known to exhibit various physiological activities such as antioxidation, anti-allergy, anti-inflammation, and antibacterial activity. However, they are representative raw materials of water insolubility or insolubility. In order to apply them as formulations, they have to be used after solubilization treatment using an excess amount of surfactant or solubilization treatment using techniques such as collection.
그러나, 놀랍게도 본 발명의 일 양태에 따른 항염 조성물이 상기 플라보노이드 성분의 용해도를 현저하게 향상시킬 수 있음을 확인하였다. 이에 따르면, 상기 플라보노이드 성분을 가용화 처리하기 위한 종래의 방법을 사용하지 않음에도 불구하고, 상기 플라보노이드 성분의 유효량 이상 가용화가 가능하다. 특히, 항염·항균 효과에서의 상승 작용을 보임은 물론이고, 플라보노이드 성분의 효능·효과를 극대화 할 수 있는 측면에서, 상기 플라보노이드 성분의 바람직한 일예로는 아피제닌, 카테킨, 다이드제인, 제니스테인, 캠퍼롤, 나린제닌, 케르세틴 등을 들 수 있으며, 이들의 당전이 유도체 또한 본 발명의 일 양태에 속한다. However, it has surprisingly been found that the anti-inflammatory composition according to one embodiment of the present invention can significantly improve the solubility of the flavonoid component. According to this, even though the conventional method for solubilizing the flavonoid component is not used, the flavonoid component can be solubilized more than an effective amount. In particular, in view of maximizing the efficacy and effect of the flavonoid component as well as a synergistic effect in the anti-inflammatory / antibacterial effect, preferred examples of the flavonoid component include apigenin, catechin, daidzein, Naringin, quercetin and the like, and their derivatives are also included in one aspect of the present invention.
일예로, 본 발명의 일 양태에 따르면, 상기 플라보노이드 성분 중 카테킨의 용해도를 200 배 이상(카테킨의 물에 대한 용해도, 5㎍/㎖)으로 현저하게 향상시킬 수 있음을 확인하였다. 또한, 케르세틴, 아피제닌(물에 대한 용해도, 5㎎/㎖ in 1M KOH) 등과 같이 염기 존재 하에서만 용해가 가능했던 플라보노이드 성분의 가용화 역시 가능케 할 수 있음 확인하였다. 즉, 본 발명에 따르면, 플라보노이드 성분의 가용화를 위해 사용되는 과량의 계면활성제 또는 염기에 의해 유발되는 안정성의 저하(일예, 변색, 변취, 역가 등의 저하) 현상을 방지할 수 있고, 상기 플라보노이드 성분의 유효량 이상 가용화 함으로써, 효능·효과를 최적으로 발현시킬 수 있어 좋다. 이때, 상기 플라보노이드의 사용량은 제한되지 않으나, 조성물 전체 중량 대비 0.001 내지 0.2 중량% 범위로 사용되는 경우, 상술된 효능·효과에 있어 우선되나 이에 한정되는 것은 아니다. For example, according to one embodiment of the present invention, it was confirmed that the solubility of catechin in the flavonoid component can be remarkably improved to 200 times or more (solubility of catechin in water, 5 μg / ml). It was also confirmed that solubilization of the flavonoid component, which was possible only in the presence of base, such as quercetin and apigenin (solubility in water, 5 mg / ml in 1 M KOH) was also possible. That is, according to the present invention, it is possible to prevent a phenomenon (for example, deterioration of discoloration, detachment, titer, etc.) caused by an excessive amount of surfactant or base used for solubilizing a flavonoid component, The effective amount and the effect can be optimally expressed. At this time, the amount of the flavonoid to be used is not limited, but when it is used in the range of 0.001 to 0.2% by weight based on the total weight of the composition, the effect is not limited to the above-mentioned effect.
본 발명의 일 양태에 따른 항염 조성물은 인터루킨-6의 발현, 인터루킨-8의 발현 및 단핵구 화학유인 단백질-1의 발현 중 하나 이상의 억제에 관여하는 것 일 수 있다.The anti-inflammatory composition according to one embodiment of the present invention may be involved in the inhibition of at least one of the expression of interleukin-6, the expression of interleukin-8, and the expression of monocyte chemoattractant protein-1.
또한, 본 발명의 일 양태에 따른 항염 조성물은 화장료 조성물 또는 약학 조성물 등으로 제형화 될 수 있다. In addition, the anti-inflammatory composition according to one embodiment of the present invention can be formulated into a cosmetic composition, a pharmaceutical composition or the like.
이때, 본 발명의 일 양태에 따른 항염 조성물을 포함하는 화장료 또는 약학 조성물은 사이토카인의 활성 억제, 피부 안전성, 제형화시의 용이성 등의 요건에 따라 적절하게 함량 범위가 조절될 수 있다. 상기 화장료 조성물 또는 약학 조성물에 있어서, 상기 항염 조성물의 사용량은 제한되지 않으나, 화장료 조성물 또는 약학 조성물 총 중량에 대하여 0.001 내지 50 중량%로 포함될 수 있으며, 바람직하게는 0.01 내지 30.0 중량%, 보다 바람직하게는 0.01 내지 20.0 중량%로 포함될 수 있다. At this time, the cosmetic composition or the pharmaceutical composition containing the anti-inflammatory composition according to one embodiment of the present invention can be appropriately controlled in content range according to requirements such as inhibition of cytokine activity, skin safety, ease of formulation, and the like. In the cosmetic composition or the pharmaceutical composition, the amount of the anti-inflammatory composition to be used is not limited, but may be in the range of 0.001 to 50% by weight, preferably 0.01 to 30.0% by weight, May be included in an amount of 0.01 to 20.0% by weight.
이하, 본 발명의 일 양태에 따른 화장료 조성물에 대하여 구체적으로 살펴본다. Hereinafter, the cosmetic composition according to one embodiment of the present invention will be described in detail.
본 발명의 일 양태에 따른 화장료 조성물은 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함하는 항염 조성물을 포함하는 항염용 화장료 조성물일 수 있다.The cosmetic composition according to an embodiment of the present invention may be a pharmaceutical composition for anti-inflammation comprising a anti-inflammatory composition comprising glyceryl glucoside and hyaluronic acid as an active ingredient.
또한, 상기 항염 조성물은 2개 이상의 수산기를 가지는 용매를 더 포함함으로써, 산뜻한 제형감의 부여와 함께 향상된 보습 효과를 갖는 화장료 조성물을 제공할 수 있다. In addition, the anti-inflammatory composition further comprises a solvent having two or more hydroxyl groups, thereby providing a cosmetic composition having an improved moisturizing effect along with imparting a fresh feeling of formulation.
일예로, 본 발명에 따른 유효성분인 글리세릴 글루코사이드 및 히알루론산에 글리세린이 혼합되어 사용될 경우, 제형 내 글리세릴 글루코사이드와 히알루론산과의 상호작용에 의한 겔링 현상을 유도하여 무겁고 미끌거리는 히알루론산 고유의 사용감을 가볍고 산뜻하게 전환시켜 줌과 동시에 부드럽게 피부에 도포되어 우수한 밀착성을 부여할 수 있다. For example, when glyceryl glucoside as an active ingredient according to the present invention and glycerin mixed with hyaluronic acid are mixed and used, a gelling phenomenon due to the interaction between glyceryl glucoside and hyaluronic acid in a formulation is induced, and a heavy and slippery hyaluronic acid The feeling of use can be lightly and neatly changed, and at the same time, it can be smoothly applied to the skin to give excellent adhesion.
또 다른 일예로, 본 발명에 따른 유효성분인 글리세릴 글루코사이드 및 히알루론산에 글리세린과 1,2-헥산디올, 1,8-옥탄디올 및 1,10-데칸디올에서 선택되는 하나 이상이 혼합된 혼합 용매의 경우, 글리세릴 글루코사이드 단독 사용 대비 현저하게 향상된 항균 효과를 나타냄과 동시에 난용성 또는 불용성 물질의 가용화능을 향상시키는 가용화제로 유용하게 사용될 수 있음을 확인하였다. As another example, glyceryl glucoside as an active ingredient according to the present invention and a mixture of glycerin and hyaluronic acid mixed with at least one selected from 1,2-hexanediol, 1,8-octanediol and 1,10-decanediol In the case of the solvent, it has been confirmed that it can be effectively used as a solubilizing agent which exhibits remarkably improved antimicrobial effect as compared with the use of glyceryl glucoside alone and improves solubility of insoluble or insoluble materials.
발명의 일 양태에 따른 화장료 조성물은 본 발명에 특별히 개시된 제조방법 이외에도, 통상적으로 알려진 제조방법을 이용하여, 일반적인 유화 제형 및 가용화 제형 등의 형태로 제조될 수 있음은 물론이다. 이때, 상기 화장료 조성물은 목적하는 바에 따라 적절하게 선택될 수 있으며, 구체적인 일예로, 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스, 팩 등으로 구성된 군으로부터 선택되는 제형으로 제형화 되는 것일 수 있으나 이에 한정되는 것은 아니다.The cosmetic composition according to an embodiment of the present invention may be prepared in the form of a general emulsified formulation and a solubilized formulation, etc., by a conventional manufacturing method, in addition to the manufacturing method specifically disclosed in the present invention. The cosmetic composition may be appropriately selected according to the purpose. For example, the cosmetic composition may be selected from the group consisting of softening agents, convergent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, And may be formulated into a formulation selected from the group consisting of flavor, essence, pack, and the like, but is not limited thereto.
일예로, 본 발명의 일 양태에 따른 화장료 조성물이 유화 제형인 경우, 담체 성분으로서, 유화제, 점증제, 유제, 오일, 왁스, 윤활제, 알코올류, 수용성 고분자제, 젤화제, 안정화제, 무기분체, 항료 등에서 선택되는 하나 이상을 사용할 수 있다. For example, when the cosmetic composition according to an embodiment of the present invention is an emulsified formulation, the emulsifier, the thickening agent, the emulsion, the oil, the wax, the lubricant, the alcohol, the water-soluble polymer, the gelling agent, , And the like can be used.
또 다른 일예로, 본 발명의 일 양태에 따른 화장료 조성물이 가용화 제형인 경우, 담체 성분으로서 용매, 용매화제 및 유탁화제 등에서 선택되는 하나 이상을 사용할 수 있다. 상기 담체 성분의 비한정적인 일예로는 물; C1~C4 알코올; 프로필렌글리콜 및 1,3-부틸글리콜 등에서 선택되는 폴리올; 글리세롤 지방족 에스테르류; 수용성 폴리펩타이드류; 폴리에틸렌글리콜 및 그 유도체에서 선택되는 수용성 고분자; Tween 20, Tween 60, 및 Tween 80 등에서 선택되는 소르비탄의 지방산 에스테르류; 등을 들 수 있으나 이에 한정되는 것은 아니다. As another example, when the cosmetic composition according to one embodiment of the present invention is a solubilized formulation, one or more selected from solvents, solubilizing agents and emulsifying agents may be used as the carrier component. Non-limiting examples of such carrier components include water; C 1 -C 4 alcohols; Propylene glycol, and 1,3-butyl glycol; Glycerol aliphatic esters; Water-soluble polypeptides; A water-soluble polymer selected from polyethylene glycol and derivatives thereof; Fatty acid esters of sorbitan selected from Tween 20, Tween 60, Tween 80 and the like; But is not limited thereto.
본 발명의 일 양태에 따른 화장료 조성물은 상기 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함하는 항염 조성물을 화장료 조성물 총 중량에 대하여, 0.001 내지 50 중량%로 포함될 수 있으며, 바람직하게는 0.01 내지 30.0 중량%, 보다 바람직하게는 0.01 내지 20.0 중량%로 포함될 수 있다. The cosmetic composition according to an embodiment of the present invention may contain 0.001 to 50% by weight, preferably 0.01 to 30.0% by weight, of the anti-inflammatory composition comprising glyceryl glucoside and hyaluronic acid as an active ingredient, %, More preferably 0.01 to 20.0% by weight.
또한, 본 발명의 일 양태에 따른 화장료 조성물은 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 폴리 펩타이드류, 고분자 다당체, 스핑고 지질 세라마이드 및 해초 엑기스 등에서 선택된 성분; 및 항염증제, NO 저해제 또는 COX-2 저해제 등에서 선택된 성분; 일 수 있으나 이에 한정되는 것은 아니다.In addition, the cosmetic composition according to an embodiment of the present invention may further include components included in a functional additive and a general cosmetic composition. Examples of the functional additives include water-soluble vitamins, oil-soluble vitamins, polypeptides, polysaccharides, sphingolipids, ceramide, and seaweed extract; And anti-inflammatory agents, NO inhibitors or COX-2 inhibitors, and the like; But is not limited thereto.
상기 일반적인 화장료 조성물에 포함되는 성분은 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조절제, 알코올, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있으나 이에 한정되는 것은 아니다.The components contained in the general cosmetic composition may be selected from the group consisting of a preservative, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, an antiseptic, a bactericide, an antioxidant, a plant extract, Perfumes, blood circulation accelerators, coolants, antiperspirants, purified water, and the like, but are not limited thereto.
이하, 본 발명의 일 양태에 따른 약학 조성물에 대하여 구체적으로 살펴본다. Hereinafter, the pharmaceutical composition according to one embodiment of the present invention will be described in detail.
본 발명의 일 양태에 따른 약학 조성물은 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함하는 항염 조성물을 포함하는 염증성 피부 질환의 예방 및 개선용 약학 조성물일 수 있다. The pharmaceutical composition according to an embodiment of the present invention may be a pharmaceutical composition for preventing and improving inflammatory skin diseases, including a anti-inflammatory composition comprising glyceryl glucoside and hyaluronic acid as an active ingredient.
이때, 상기 약학 조성물은 인간을 포함한 동물에 직접 적용될 수 있다. 상기 동물은 식물에 대응하는 생물군으로 주로 유기물을 영양분으로 섭취하고, 소화기관, 배설기관 및 호흡기관이 분화되어 있는 것을 말하며, 좋게는 포유류, 더욱 좋게는 인간일 수 있다.At this time, the pharmaceutical composition can be directly applied to animals including humans. The animal is a group of organisms corresponding to plants. It mainly consumes organic matter as nutrients, and differentiates digestive organs, excretory or respiratory organs. Preferably, it is a mammal, preferably a human.
본 발명의 일 양태에 따른 화장료 조성물은 상기 글리세릴 글루코사이드 및 히알루론산을 유효성분으로 포함하는 항염 조성물을 약학 조성물 총 중량에 대하여, 0.001 내지 50 중량%로 포함될 수 있으며, 바람직하게는 0.01 내지 30.0 중량%, 보다 바람직하게는 0.01 내지 20.0 중량%로 포함될 수 있다. The cosmetic composition according to an embodiment of the present invention may contain 0.001 to 50% by weight, preferably 0.01 to 30.0% by weight, of the anti-inflammatory composition comprising glyceryl glucoside and hyaluronic acid as an active ingredient, %, More preferably 0.01 to 20.0% by weight.
본 발명의 일 양태에 따른 상기 약학 조성물은 경구 또는 비경구의 여러 가지 형태로 제형화 될 수 있음은 물론이다. 상기 약학 조성물은 통상의 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함할 수 있음은 물론이다. The pharmaceutical composition according to an embodiment of the present invention may be formulated into various forms such as oral or parenteral form. The pharmaceutical composition may contain diluents or excipients such as conventional fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like.
일예로, 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 연질 또는 경질 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 또 다른 일예로, 경구 투여를 위한 액상제제에는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. For example, solid preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, etc. These solid preparations may contain one or more excipients such as starch, calcium carbonate, sucrose (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. As another example, liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, And the like.
또 다른 일예로, 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁용제, 유제, 동결건조 제제, 좌제 등이 포함된다. 상기 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.As another example, formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 일 양태에 따른 약학 조성물은 목적하는 바에 따라 비경구 투여하거나 경구 투여할 수 있으며, 하루에 체중 1 ㎏당 0.01~500 ㎎, 바람직하게는 0.1~100 ㎎의 양으로 투여되도록 1 내지 수회에 나누어 투여할 수 있다. 특정 환자에 대한 투여용량은 환자의 체중, 연령, 성별, 건강 상태, 식이, 투여 시간, 투여 방법, 배설률, 질환의 중증도 등에 따라 변화될 수 있다.The pharmaceutical composition according to one embodiment of the present invention may be administered parenterally or orally, and may be administered in an amount of 0.01 to 500 mg, preferably 0.1 to 100 mg, per 1 kg of body weight per day, . ≪ / RTI > The dosage for a particular patient may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate, severity of disease, and the like.
또 다른 일예로, 외용제에는 멸균된 수용액, 비수성용제, 유화제, 점증제, 유제, 오일, 왁스, 윤활제, 알코올류, 수용성 고분자제, 젤화제, 안정화제, 무기분체, 항료, pH 조절제, 방부제 등에서 선택되는 하나 이상이 포함될 수 있다. As another example, the external preparation may contain at least one selected from the group consisting of sterilized aqueous solution, non-aqueous solvent, emulsifier, thickener, emulsion, oil, wax, lubricant, alcohol, water-soluble polymer, gelling agent, stabilizer, inorganic powder, One or more selected may be included.
본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 연질 또는 경질 캡슐제, 현탁액, 에멀젼, 시럽, 분무제 등의 경구형 제형, 연고, 로션, 크림, 겔, 패취, 분무제 등의 외용제, 좌제, 주사제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 제형화하여 사용될 수 있다. 이때, 본 발명에서는 연고, 로션, 크림, 겔, 패취, 분무제 등의 외용제 형태의 약학 조성물이 우선되나 이에 한정되는 것은 아니다.The pharmaceutical composition according to the present invention can be administered orally or parenterally in the form of powders, granules, tablets, soft or hard capsules, oral preparations such as suspensions, emulsions, syrups and sprays, ointments, lotions, creams, gels, And the like, suppositories, injections, sterile injectable solutions, etc., and may be formulated in any form suitable for pharmaceutical preparations. At this time, the pharmaceutical composition in the form of an external preparation such as ointment, lotion, cream, gel, patch, spray, etc. is preferred, but the present invention is not limited thereto.
또한, 본 발명의 일 양태에 따른 약학 조성물은 상기 유효성분 이외에 공지의 항염 효과가 있는 것으로 인정된 물질, 일 예로 항염증제, NO 저해제 또는 COX-2 저해제 등으로 사용되는 물질을 더 포함할 수 있음은 물론이다.In addition, the pharmaceutical composition according to an embodiment of the present invention may further comprise a substance used as a known substance having a known anti-inflammatory effect, such as an anti-inflammatory agent, an NO inhibitor or a COX-2 inhibitor, Of course.
본 발명의 일 양태에 따른 약학 조성물은 염증성 피부 질환의 예방 및 개선 효과를 가진다. 상기 염증성 피부 질환의 비한정적인 일예로는 아토피 피부염, 건선, 접촉성 피부염, 습진성 피부염, 광선 피부염, 지루 피부염, 포진성 피부염, 편평태선, 경화태선, 괴저성 농피증, 천포창, 수포성 표피박리증, 전신성 경화증, 피부근염, 다발성근염, 염증성 근병변, 나병 또는 세자리 증후군일 수 있으며, 특히 아토피 피부염, 건선, 접촉성 피부염 등의 개선 효과가 탁월하다. The pharmaceutical composition according to one aspect of the present invention has an effect of preventing and improving inflammatory skin diseases. Non-limiting examples of the inflammatory skin disease include atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, dermatitis dermatitis, dermatitis dermatitis, herpes dermatitis, herpes dermatitis, squamous cell carcinoma, gingivosclerosis, pemphigus, , Systemic sclerosis, dermatomyositis, multiple myositis, inflammatory muscle lesion, leprosy or triceps, and particularly excellent effects such as atopic dermatitis, psoriasis, contact dermatitis and the like are excellent.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예는 단지 예시적인 것이지 본 발명의 범위를 어떤 식으로든 제한하기 위한 것은 아니다. Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the following examples are merely illustrative and not intended to limit the scope of the present invention in any way.
(세포독성 확인) (Confirm cytotoxicity)
하기 실시예 및 비교예에서 제조된 조성물을 이용하여, 사람의 섬유아세포(ATCC 2076)에 대한 세포생존율을 측정하였다. 사람의 섬유아세포(ATCC 2076)를 5x104cells/ml의 농도로 하여, 소혈청 10%를 함유한 IMDM (Iscove's Modified Dulbecco's Medium, GIBCO) 24웰 배양판에 접종하였다. 접종 후 24시간 후 혈청이 없는 배지로 교체한 다음, 시험 시료를 1, 10 , 100 ㎍/㎖의 농도로 첨가하여 하루 동안 37 ℃, 5% CO2인큐베이터에서 배양하였다. 배양 후 상등액을 제거 하고 다시 5% PBS(phosphate buffered saline)를 200 ul씩 가하여 세척하였다. 다음으로, MTT 용액을 웰당 1.0㎖씩 가한 후 4시간 후에 MTT를 제거한 후 DMSO를 웰당 1.0㎖씩을 가하여, 15시간 동안 37℃에서 인큐베이션하였다. 이후, 570nm에서 흡광도를 측정 하고, 하기 식 1을 이용하여 세포 생존율을 구하였다. 그 결과를 하기 표 2에 나타내었다. 이때, 음성 대조군으로는 상기 유효성분을 사용하지 않은 무처리구를 채택하였다.Using the compositions prepared in the following Examples and Comparative Examples, the cell viability of human fibroblasts (ATCC 2076) was measured. Human fibroblast (ATCC 2076) was inoculated into a 24-well culture plate of IMDM (Iscove's Modified Dulbecco's Medium, GIBCO) containing 10% bovine serum at a concentration of 5 x 10 4 cells / ml. After 24 hours of inoculation, the medium was replaced with serum-free medium. Then, the test sample was added at a concentration of 1, 10, 100 μg / ml and cultured in a 5% CO 2 incubator at 37 ° C. for one day. After the incubation, the supernatant was removed and further washed with 200 μl of 5% PBS (phosphate buffered saline). Next, 1.0 ml of MTT solution was added to each well, MTT was removed after 4 hours, 1.0 ml of DMSO was added to each well, and the mixture was incubated at 37 ° C for 15 hours. Thereafter, the absorbance at 570 nm was measured, and the cell viability was determined using the following formula (1). The results are shown in Table 2 below. At this time, as the negative control group, an untreated control group without the active ingredient was employed.
(식 1)(Equation 1)
세포 생존율(%) = (A570λ값/B570λ값) × 100Cell survival rate (%) = (A 570? Value / B 570? Value ) × 100
A: 실시예의 570nm에서 흡광도값A: absorbance value at 570 nm of the example
B: 음성대조군의 570nm에서 흡광도값B: absorbance value at 570 nm of negative control group
(항염 효능 평가) (Evaluation of anti-inflammatory activity)
하기 실시예 및 비교예에서 제조된 조성물을 이용하여, 대식세포주에서 LPS 자극에 의한 IL-8, MCP-1 및 IL-6 억제 효능을 평가하였다. 인간 대식 세포주(Human macrophage cell line)인 THP-1 cell(한국세포주은행(KCLB), 40202)을 6-well plate에 2×106 cells/well이 되도록 seeding하고 12시간 동안 세포 배양기에서 배양하였다.The compositions prepared in the following examples and comparative examples were used to evaluate IL-8, MCP-1 and IL-6 inhibitory activity by LPS stimulation in macrophage cells. Human macrophage cell line THP-1 cells (KCLB, 40202) were seeded at 6 × 10 6 cells / well in a 6-well plate and cultured in a cell incubator for 12 hours.
여기에, 상기 실시예 1에서 제조한 항염 조성물의 최종 농도가 각각 1, 10 , 100 ㎍/㎖이 되도록 처리하고, 21시간 뒤에 LPS의 최종 농도가 20 ㎍/㎖이 되도록 추가처리하여 24 시간 동안 배양시켰다. 배양액 50 ㎕를 취하여 인터루킨-8 (Interleukin-8; IL-8), 단핵구 화학유인 단백질-1 (Monocyte chemoattractant protein-1; MCP-1), 인터루킨-6 (Interleukin-6; IL-6) ELISA 키트 (입수처: BD pharmigen, USA)를 이용하여 LPS에 의한 IL-8, MCP-1, IL-6 유리 억제 효과(억제능)를 측정하여 그 결과를 하기 표 3에 나타내었다.Then, the final concentration of the anti-inflammatory composition prepared in Example 1 was adjusted to 1, 10, and 100 / / ml, respectively. After 21 hours, the final concentration of LPS was further adjusted to 20 / / Lt; / RTI > (IL-8), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6) ELISA kit (Inhibitory effect) of IL-8, MCP-1, and IL-6 by LPS was measured using a commercially available anti-inflammatory agent (BD pharmigen, USA)
상기 억제능은 표준물질인 유전자 재조합형 IL-8, MCP-1, IL-6의 각 흡광도를 토대로 표준 곡선을 그려 흡광도와 표준물질간의 반응식을 구한 후, 처리된 각각의 배양액의 흡광도를 대입하여, 인터루킨-8 또는 단핵구 화학유인 단백질-1의 분비량을 얻었다. 이후 아래의 식 1에 의해 자극완화율을 평가하였다.The inhibitory activity was determined by plotting standard curves based on the respective absorbances of the recombinant IL-8, MCP-1 and IL-6, which are standard substances, to calculate the reaction equation between the absorbance and the standard substance, Secretion of interleukin-8 or monocyte chemoattractant protein-1 was obtained. Then, the stimulation relaxation rate was evaluated by the following equation (1).
(식 1)(Equation 1)
자극완화율(%) = 100 x [1-(LPS과 처리군에서의 IL-8, MCP-1 또는 IL-6 분비증가량/ LPS 단독처리군에서의 IL-8, MCP-1 또는 IL-6 분비증가량)]IL-8, MCP-1 or IL-6 in the treated group / IL-8, MCP-1 or IL-6 increased in the treated group / 100% Increased secretion)]
(항균 효능 평가) (Evaluation of antibacterial activity)
하기 실시예 및 비교예에서 제조된 조성물의 항균 활성을 측정하기 위해, 박테리아로는 그람양성균으로 황색포도상구균(Staphylococcus aureus ATCC 6538P), 그람음성균으로 대장균(Escherichia coli ATCC 8739), 녹농균(Pseudomonas aeruginosa ATCC 9027), 효모로는 칸디다 알비칸스(Candida albicans ATCC 10231), 아스퍼질러스 나이거(Aspergillus niger ATCC22343)을 사용하였다. Staphylococcus aureus ATCC 6538P as a gram-positive bacterium, Escherichia coli ATCC 8739 as a gram-negative bacterium, Pseudomonas aeruginosa ATCC 8738 as a gram-positive bacterium for measuring the antimicrobial activity of the compositions prepared in the following Examples and Comparative Examples, 9027), Candida albicans ATCC 10231 and Aspergillus niger ATCC 22343 were used as yeast.
배양한 각각의 균주를 응고된 평판 배지 위에 약 50㎕를 가하여 평판배지에 분주하고 스프레더(spreader)를 이용하여 균일하게 도말 하였다. 각각의 조성물을 지름이 10mm인 페이퍼디스크(paper disk)에 약 40 ㎕를 흡수시킨 후 용매를 건조시키고 균주가 도말된 배지 표면상에 밀착시켜 30 ℃조건의 배양기에서 48 시간 이상 배양 후 페이퍼디스크 주변에 형성된 투명환 (clear zone)의 크기를 측정하여 항균 효과를 확인하였다. 미생물은 페이퍼디스크 근처에서 생장을 못하므로 평균직경 값이 넓어질수록 항균활성이 우수하다. 또한, 양성 대조군으로 메틸 파라벤(methyl paraben, MP)을 사용하여 동일한 방법으로 실시하였다. 이때, 직경이 클수록 해당 균주에 대해 항균 효과가 높음을 의미하며, 그 결과를 하기 표 4에 나타내었다.Approximately 50 μl of each of the cultivated strains was added to a solidified plate medium, and the mixture was dispensed into a plate culture medium and uniformly smoothed using a spreader. About 40 μl of each composition was absorbed into a paper disk having a diameter of 10 mm, the solvent was dried, the microorganism was closely adhered to the surface of the medium on which the strain had been coated, and cultured in an incubator at 30 ° C. for more than 48 hours. And the size of the clear zone formed in the test piece was measured to confirm the antibacterial effect. Since microorganisms can not grow near the paper disk, the larger the average diameter value, the better the antimicrobial activity. In addition, methylparaben (MP) was used as a positive control, and the same procedure was followed. At this time, the greater the diameter, the higher the antibacterial effect of the strain. The results are shown in Table 4 below.
(실시예 1-5) (Example 1-5)
하기 표 1의 조성으로 항염 조성물을 제조한 후 상기의 방법으로 세포독성 및 항염·항균 효과를 평가하였다.After preparing the anti-inflammatory composition according to the composition shown in the following Table 1, cytotoxicity and anti-inflammation / antibacterial effect were evaluated by the above-mentioned method.
(비교예 1-6)(Comparative Example 1-6)
하기 표 1의 조성으로 조성물을 제조한 후 상기 상기의 방법으로 세포독성 및 항염·항균 효과를 평가하였다.After preparing the composition with the composition shown in the following Table 1, cytotoxicity and anti-inflammation / antibacterial effect were evaluated by the above-mentioned method.
상기 표 1의 조성으로 제조된 조성물에 있어서, 비교예 4 내지 6의 경우, 제형이 불안정하게 형성되어 유화 후 1일 이내 (-)-카테킨의 침전 현상이 발견되었으며, 특히 비교예 4 및 5의 안정성이 불량하였다. (-) - catechin was found to precipitate within 1 day after emulsification in the case of the compositions prepared in the composition of Table 1, and in Comparative Examples 4 to 6, especially in Comparative Examples 4 and 5 The stability was poor.
상기 표 2에 도시한 바에 따르면, 본 발명에 따른 항염 조성물은 무처리구에 비하여 세포 생존율이 거의 감소하지 않았다. 이는 본 발명에 따른 항염 조성물이 상기 시험농도에서 세포에 대한 독성을 나타내지 않는 다는 것을 의미한다. 더욱이, 본 발명에 따른 특정 비율을 만족하는 경우 세포 독성에 탁월함을 보임을 알 수 있었다. As shown in Table 2, the cell survival rate of the anti-inflammatory composition according to the present invention was not substantially reduced as compared with the control. This means that the anti-inflammatory composition according to the present invention does not show toxicity to the cells at the test concentration. Furthermore, it was found that when the specific ratio according to the present invention is satisfied, it is excellent in cytotoxicity.
상기 표 3에 도시한 바에 따르면, 본 발명에 따른 항염 조성물은 대식세포에서 염증 관련 사이토카인(IL-6 등)과 케모카인(IL-8, MCP-1 등)을 효과적으로 억제시킴과 동시에 LPS 자극 후 대식세포에서 분비되는 NO형성을 억제함으로써, 탁월한 항염 효과를 갖는다. As shown in Table 3, the anti-inflammatory composition according to the present invention effectively inhibits inflammation-related cytokines (such as IL-6) and chemokines (such as IL-8 and MCP-1) By inhibiting NO formation secreted from macrophages, it has an excellent anti-inflammatory effect.
특히, 글리세릴 글루코사이드 또는 히알루론산을 단독으로 사용한 비교예 1 및 2 대비, IL-6의 발현 억제는 최대 220% 이상, MCP-1 의 발현 억제는 최대 197% 이상, IL-8의 발현 억제는 최대 410% 이상으로 현저하게 향상된 항염 효과를 보임을 확인할 수 있다(비교예 2_100㎍/㎖ vs 실시예 4_100㎍/㎖). 또한, 본 발명에 따른 항염 조성물은 농도 의존적으로 IL-8, MCP-1 및 IL-6의 분비가 억제되며, 특히, 100 ㎍/㎖의 농도일 때, 각 억제능이 최대가 되는 것을 확인 할 수 있었다. In particular, inhibition of IL-6 expression was inhibited by at most 220%, inhibition of MCP-1 expression was inhibited by at least 197%, and inhibition of IL-8 expression was inhibited by the inhibition of IL-6 expression in comparison with Comparative Examples 1 and 2 in which glyceryl glucoside or hyaluronic acid alone was used It is confirmed that the anti-inflammatory effect remarkably improved to at most 410% (Comparative Example 2 100 μg / ml vs Example 4 100 μg / ml). In addition, the anti-inflammatory composition according to the present invention suppresses the secretion of IL-8, MCP-1 and IL-6 in a concentration-dependent manner, and especially when the concentration is 100 μg / ml, there was.
게다가, 본 발명에 따른 항염 조성물은 물에 대한 용해도가 매우 낮거나 불용성인 폴리페놀류(일예, 카테킨, 케르세틴 등)의 가용화능(solubilization ability)을 향상시켜, 본 발명에 따른 효능·효과에 시너지를 나타낼 수 있음을 확인하였다.In addition, the anti-inflammatory composition according to the present invention improves the solubilization ability of polyphenols (e.g., catechins, quercetin, etc.) having a very low solubility in water or insoluble therein, Respectively.
상기 표 4에서 도시된 바와 같이, 본 발명에 따른 항염 조성물은 뛰어난 항염 효과 뿐 아니라 항균 효과에 있어, 현저하게 향상된 시너지 효과를 나타냄을 알 수 있었다. 상술된 항균에 대한 효과는 합성 항균제로 알려진 메틸 파라벤에 준하는 것이다. As shown in Table 4, it was found that the anti-inflammatory composition according to the present invention exhibits remarkably improved synergistic effect in antibacterial effect as well as excellent anti-inflammatory effect. The above-mentioned effect on antibacterial is based on methylparaben known as synthetic antimicrobial agent.
요컨데, 본 발명에 따르면 피부 부작용을 유발하지 않으며, 피부 염증을 효과적으로 억제할 수 있는 항염 조성물을 제공할 수 있다. 더불어, 본 발명에 따르면 피부에 대한 우수한 밀착성으로 염증성 피부 질환의 예방 및 개선에 이상적인 약리작용 및 효능·효과를 부여할 수 있어, 새로운 항염용 원료로 다양한 양태로 제형화 되어 활용될 수 있을 것으로 기대된다.According to the present invention, it is possible to provide a anti-inflammatory composition that does not cause skin side effects and can effectively inhibit skin inflammation. In addition, according to the present invention, it is possible to impart an ideal pharmacological action, an effect and an effect to the prevention and improvement of an inflammatory skin disease by the excellent adhesion to the skin, and it can be formulated into various forms as a new anti- do.
(제형예 1)(Formulation Example 1)
하기 표 5의 조성으로 통상의 방법에 따라 화장수를 제조하였다.Lotions were prepared according to a conventional method with the compositions shown in Table 5 below.
(제형예 2)(Formulation Example 2)
하기 표 6의 조성으로 통상의 방법에 따라 영양 크림을 제조하였다.Nutrition cream was prepared according to a conventional method with the composition shown in Table 6 below.
(제형예 3)(Formulation Example 3)
하기 표 7의 조성으로 통상의 방법에 따라 연고를 제조하였다.Ointment was prepared according to a conventional method with the composition shown in Table 7 below.
(제형예 4)(Formulation Example 4)
하기 표 8의 조성으로 통상의 방법에 따라 겔을 제조하였다.A gel was prepared according to a conventional method with the composition shown in Table 8 below.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정하여 진다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the technical scope of the present invention is not limited to the disclosed exemplary embodiments. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (12)
2개 이상의 수산기를 가지는 용매를 더 포함하는 항염 조성물.The method according to claim 1,
Further comprising a solvent having two or more hydroxyl groups.
상기 수산기를 가지는 용매는 글리세린, 1,3-프로판디올, 1,3-부탄디올, 1,5-펜탄디올, 1,2-헥산디올, 1,8-옥탄디올 및 1,10-데칸디올에서 선택되는 하나 이상인 항염 조성물.3. The method of claim 2,
The solvent having a hydroxyl group is selected from glycerin, 1,3-propanediol, 1,3-butanediol, 1,5-pentanediol, 1,2-hexanediol, 1,8-octanediol and 1,10- Lt; / RTI >
플라보노이드를 더 포함하는 항염 조성물.3. The method of claim 2,
≪ / RTI > further comprising a flavonoid.
상기 플라보노이드는 아피제닌, 카테킨, 다이드제인, 제니스테인, 캠퍼롤, 나린제닌, 케르세틴 및 이들의 당전이 유도체로 이루어진 군에서 선택되는 것인 항염 조성물.5. The method of claim 4,
Wherein the flavonoid is selected from the group consisting of apigenin, catechin, daidzein, genistein, camperol, naringinin, quercetin, and derivatives thereof.
상기 글리세릴 글루코사이드 및 히알루론산은 1: 0.1 내지 1:2 중량비로 혼합되는 것인 항염 조성물.The method according to claim 1,
Wherein the glyceryl glucoside and hyaluronic acid are mixed in a weight ratio of 1: 0.1 to 1: 2.
상기 항염 조성물은 인터루킨-6의 발현, 인터루킨-8의 발현 및 단핵구 화학유인 단백질-1의 발현 중 하나 이상의 억제에 관여하는 것인 항염 조성물.The method according to claim 1,
Wherein said anti-inflammatory composition is involved in the inhibition of at least one of the expression of interleukin-6, the expression of interleukin-8, and the expression of monocyte chemoattractant protein-1.
상기 항염 조성물은 약학 조성물 또는 화장료 조성물인 항염 조성물.The method according to claim 1,
Wherein the anti-inflammatory composition is a pharmaceutical composition or a cosmetic composition.
상기 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩으로 제형화되는 것인 항염 조성물.9. The method of claim 8,
Wherein the cosmetic composition is formulated into a softening agent, a convergent lotion, a nutritional lotion, an eye cream, a nutritional cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, an essence or a pack.
상기 약학 조성물은 로션, 연고, 겔, 크림, 패취 또는 분무제로 제형화되는 것인 항염 조성물.9. The method of claim 8,
Wherein the pharmaceutical composition is formulated into a lotion, ointment, gel, cream, patch or spray.
상기 약학 조성물은 염증성 피부 질환의 예방 및 개선용 항염 조성물.9. The method of claim 8,
The pharmaceutical composition is useful as an anti-inflammatory agent for the prevention and / or amelioration of inflammatory skin diseases.
상기 염증성 피부 질환은 아토피피부염, 건선, 접촉성피부염, 습진성 피부염, 광선 피부염, 지루 피부염, 포진성 피부염, 편평태선, 경화태선, 괴저성 농피증, 천포창, 수포성 표피박리증, 전신성 경화증, 피부근염, 다발성근염, 염증성 근병변, 나병 또는 세자리 증후군인 항염 조성물.12. The method of claim 11,
The inflammatory skin disease is selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, dermatitis dermatitis, dermatitis dermatitis, herpes dermatitis, herpes zoster dermatitis, squamous cellulitis, scleroderma, gangrenous epidermolysis, , Multiple myositis, inflammatory muscle lesions, leprosy or triceps.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160162821A KR101911377B1 (en) | 2016-12-01 | 2016-12-01 | Composition for anti-inflammatory |
PCT/KR2016/014079 WO2018101517A1 (en) | 2016-12-01 | 2016-12-02 | Anti-inflammatory composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160162821A KR101911377B1 (en) | 2016-12-01 | 2016-12-01 | Composition for anti-inflammatory |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180062763A true KR20180062763A (en) | 2018-06-11 |
KR101911377B1 KR101911377B1 (en) | 2018-10-25 |
Family
ID=62242608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160162821A KR101911377B1 (en) | 2016-12-01 | 2016-12-01 | Composition for anti-inflammatory |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101911377B1 (en) |
WO (1) | WO2018101517A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109381367B (en) * | 2018-12-17 | 2021-11-12 | 贺鹏 | Special protein cream for infants |
CN113712841B (en) * | 2021-11-01 | 2022-02-11 | 深圳市萱嘉生物科技有限公司 | Application of glycerol glucoside in preparation of oral care product |
CN116473901B (en) * | 2023-06-12 | 2023-11-07 | 广州丽彦妆生物科技有限公司 | Moisturizing and repairing freeze-dried mask and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100563548B1 (en) | 2004-05-18 | 2006-03-27 | 한불화장품주식회사 | A cosmetic composition containing an extract of sorbus commixta |
KR100697319B1 (en) | 2005-05-30 | 2007-03-20 | 한불화장품주식회사 | Method for manufacturing extract of sorbus commixta having increased amount of flavonoid and cosmetic composition containing same |
KR101141802B1 (en) | 2009-10-30 | 2012-05-04 | (주)아모레퍼시픽 | Cosmetic composition for improving the male skin |
KR101309172B1 (en) | 2005-06-29 | 2013-09-17 | 주식회사 엘지생활건강 | Composition for preventing from inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007323468A1 (en) * | 2006-11-22 | 2008-05-29 | Ocumedic Aps | Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye |
KR101162331B1 (en) * | 2010-04-02 | 2012-07-04 | 주식회사 진켐 | Method for Preparing Glycosylated Flavonoids |
ES2665254T3 (en) * | 2011-07-12 | 2018-04-25 | Holy Stone Healthcare Co., Ltd. | Compositions comprising hyaluronic acid for treatment and prevention of mucosal related diseases |
MX2014006285A (en) * | 2011-11-24 | 2014-10-24 | Toyo Sugar Refining Co Ltd | Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent. |
US20150118334A1 (en) * | 2012-06-17 | 2015-04-30 | Kamedis Ltd | Topical compositions for the treatment of chronic inflammatory skin disease |
-
2016
- 2016-12-01 KR KR1020160162821A patent/KR101911377B1/en active IP Right Grant
- 2016-12-02 WO PCT/KR2016/014079 patent/WO2018101517A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100563548B1 (en) | 2004-05-18 | 2006-03-27 | 한불화장품주식회사 | A cosmetic composition containing an extract of sorbus commixta |
KR100697319B1 (en) | 2005-05-30 | 2007-03-20 | 한불화장품주식회사 | Method for manufacturing extract of sorbus commixta having increased amount of flavonoid and cosmetic composition containing same |
KR101309172B1 (en) | 2005-06-29 | 2013-09-17 | 주식회사 엘지생활건강 | Composition for preventing from inflammation |
KR101141802B1 (en) | 2009-10-30 | 2012-05-04 | (주)아모레퍼시픽 | Cosmetic composition for improving the male skin |
Also Published As
Publication number | Publication date |
---|---|
WO2018101517A1 (en) | 2018-06-07 |
KR101911377B1 (en) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100795225B1 (en) | Skin topical composition comprising Iris germanica, Centella asiatica Urbain, Matricaria chamomilia, Oenothera odorate Jacq. and Houttuynia cordata Thunb. for improvement of a pimpled skin | |
KR20190041865A (en) | Composition for preventing or treating hair loss comprising enterococcus faecalis | |
EP2575971B1 (en) | Combined plant extracts for use in the treatment of microbial infections | |
KR101015702B1 (en) | Compositions comprising Seaweeds extract for improving and alleviating inflammation and irritation of skin | |
US8835496B2 (en) | Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride for treating of skin, mucosa, hair, nails, or scalp | |
KR101911377B1 (en) | Composition for anti-inflammatory | |
KR101831883B1 (en) | Cosmetic composition for anti-itching effect comprising isosecotanapartholide | |
KR101838404B1 (en) | Composition for preventing or treating Acne containing oligo-chitosan as an effective component | |
KR20090130584A (en) | Cosmetic composition comprising an extract of mixed herbs having skin whitening and wrinkle improving activity | |
KR20070003365A (en) | Cosmetic composition comprising the extract of crinum asiaticum linne var. having anti-allergic and anti-inflammatory activity | |
WO2011115061A1 (en) | Hyaluronic acid production promoter | |
KR20240004199A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
KR20190012324A (en) | Seaweed extract for treating skin inflammatory diseases and composition containing the same | |
KR20230120619A (en) | Composition for improving skin conditions | |
KR20210077365A (en) | Cosmetic composition comprising colocasia esculenta biorenovate extract and method of preparing the same | |
KR20120062615A (en) | External composition for skin using an extract or a fraction of padina arborescens | |
KR20150050631A (en) | Cosmetic Composition and Topical Composition for Anti-inflammation Containing Coprisin Peptide Derivative CopA | |
KR20180017974A (en) | Cosmetic composition for preventing or treating acne comprising combined herbal extracts | |
KR102488864B1 (en) | Composition Containing Terminalia Chebula Extract and Artemisia Extract for Controlling Skin Bacterial Flora Growth, or Enhancing Skin Immunity | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR20210117027A (en) | Composition for skin whitening and method for whitening the skin | |
KR20150102449A (en) | Composition comprising an extract of crude drug for treating and improving skin-aging or skin trouble | |
KR101409111B1 (en) | Composition for treating or preventing acne comprising Caffeic acid or its derivative as an active ingredient | |
KR101557788B1 (en) | Cosmetic Composition and Topical Composition for Anti-inflammation Containing Peptide derived from Harmonia axyridis larva | |
KR101576337B1 (en) | Composition for prevention or improving of inflammatory skin disease, or anti-oxidation comprising Zea mays leaves extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |